{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-217484","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.567058+00:00","generated_at":"2026-05-17T05:40:11.541042+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intellia reports nex-z Phase 1 data: 92% mean TTR reduction at 24 months, 72% of patients show mNIS+7 improvement","bullets":["Mean serum TTR reduction of 92% at 24 months (n=33) and 90% at 36 months (n=12) after single dose.","72% of evaluable patients (13/18) achieved ≥4-point improvement in mNIS+7 by month 24; most who had progressed on patisiran improved.","89% of all 36 patients showed improvement or stability in PND scores through 24 months; mBMI, QoL-DN, NfL all trended toward improvement.","Nex-z generally well tolerated; infusion-related reactions mild/moderate, no discontinuations; three Grade ≥3 liver enzyme elevations resolved spontaneously.","Phase 3 MAGNITUDE-2 enrollment (approx. 50 patients) expected to complete in H1 2026; BLA submission for ATTRv-PN targeted by 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-217484","json":"https://secwatch.observer/filing/0001193125-25-217484.json","markdown":"https://secwatch.observer/filing/0001193125-25-217484.md","text":"https://secwatch.observer/filing/0001193125-25-217484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525217484/0001193125-25-217484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525217484/d870108d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:40:11.541042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}